Washington, D.C. (July 11, 2013) – The National Osteoporosis Foundation (NOF), the nation’s leading health organization dedicated to preventing osteoporosis and broken bones, has named Taylor C. Wallace, PhD, CFS, FACN, as its Senior Director of Science Policy and Government Relations. With his extensive scientific and regulatory experience in food science and nutrition, Dr. Wallace will drive NOF’s focus on health and nutrition as key components of osteoporosis prevention.
Dr. Wallace joins NOF from the Council for Responsible Nutrition (CRN), the dietary supplement industry’s leading trade association, where he served as the Senior Director of Scientific & Regulatory Affairs, providing expertise to evaluate emerging research and ensure the organization’s legislative and policy positions were based on credible science. During his tenure at CRN, Dr. Wallace spearheaded nutrition policy initiatives and developed new scientific reviews and original research for peer reviewed literature.
“With NOF’s latest prevalence data showing that approximately nine million adults in the U.S. have osteoporosis and an additional 48 million have low bone mass, there’s never been a more urgent need for comprehensive science, policy and legislative agendas to reduce the incidence of this debilitating disease,” Dr. Wallace said. “Only by working with congressional champions and like-minded corporate and government partners can we achieve our goal of educating the public and motivating them to take action and protect their bones.”
“Taylor brings the perfect mix of scientific and legislative experience we need to drive our efforts to educate and advocate for better bone health at the national level,” said NOF CEO and Executive Director, Amy Porter. “With his deep background in food science and nutrition, Taylor’s addition to the NOF executive team underscores our commitment to preventing osteoporosis and broken bones by promoting the importance of diet and exercise as key components to building strong bones for life.”
Dr. Wallace is responsible for developing NOF’s scientific, legislative and policy program to ensure that it is comprehensive and evidence-based with the goal of improving the nation’s bone health and decreasing the prevalence of osteoporosis. To implement NOF’s programs, Dr. Wallace will work with key government agencies and scientific societies to improve the tests and therapies available to prevent, diagnose and treat osteoporosis.
Dr. Wallace’s academic background includes a PhD and an MS in Food Science and Nutrition from The Ohio State University and a BS in Food Science and Technology from the University of Kentucky. Dr. Wallace currently serves as a Trustee and the acting Treasurer of Feeding Tomorrow, the Foundation of the Institute of Food Technologists. Dr. Wallace was recently elected a fellow of the American College of Nutrition and he is also a member of the editorial board for the Journal of the American College of Nutrition. He has produced more than 20 peer-reviewed publications and book chapters and is the co-editor of Anthocyanins in Health and Disease Prevention and the editor of Dietary Supplements in Health and Disease Prevention to be published in 2014.
# # #
About the National Osteoporosis Foundation
Established in 1984, NOF is the nation’s leading health organization dedicated to preventing osteoporosis and broken bones, promoting strong bones for life and reducing human suffering through programs of awareness, education, advocacy, and research. For more information on the National Osteoporosis Foundation, visit www.nof.org.
NOF Clinical Director, Dr. Andrea Singer, is featured in a Reuters article detailing a new study on the toll of osteoporotic fratures among postmenopausal women. Dr. Singer served as lead author of the study that found bone fractures due to osteoporosis lead to more hospitalizations and greater healthcare costs than heart attack, stroke or breast cancer for U.S. women age 55 or older.
The December issue of Consumer Reports on Health announces "Good News about Osteoporosis Meds." A recent review of 294 studies completed since 2005 concluded that certain drugs to treat low bone density can reduce the risk of a spinal fracture by 40 to 60 percent in high risk women, and other fractures can be reduced by 20 to 40 percent.